ArticleInternational journal of clinical and experimental medicine2015
Evaluating the microRNA-target gene regulatory network in renal cell carcinomas, identification for potential biomarkers and critical pathways.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Kidney Cancer and Chronic Kidney Disease: Too Close for Comfort.Biomedicines · 2021Review
- MicroRNA Signature in Renal Cell Carcinoma.Frontiers in oncology · 2020Review
- Decreased expression of apoptosis-inducing factor in renal cell carcinoma is associated with poor prognosis and reduced postoperative survival.Oncology letters · 2019Article
- Potential clinical applications of microRNAs as biomarkers for renal cell carcinoma.Central European journal of urology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Variant microRNA (miRNA) expression is a character of many cancer types. The combined analysis of miRNA and messenger RNA (mRNA) expression profiles is crucial to identifying links between deregulated miRNAs and oncogenic pathways. The aim of this study was to screen several novel genes associated with renal cell carcinoma (RCC), and analyze the gene functions and signal pathways which were critical to RCCs with DNA microarray. The gene expression profile of GSE6344 was downloaded from Gene Expression Omnibus database, including 10 RCC samples and 10 healthy controls. Compared with the control samples, differentially expressed genes (DEGs) of RCC was identified. The selected DEGs were further analyzed using bioinformatics methods. Gene ontology (GO) enrichment analysis was performed using Gene Set Analysis Toolkit and protein-protein interaction (PPI) network was constructed with prePPI. Then, pathway enrichment analysis to PPI network was performed using WebGestalt software. We found that a total of 521 DEGs were down-regulated and 473 DEGs were up-regulated in RCC samples compared to healthy controls. A total of 15 remarkable enhanced functions and 17 suppressed functions were identified. PPI nodes of high degrees, such as RHCG, RALYL, SLC4A1, UMOD and CA9, were obtained. The DEGs were classified and significantly enriched in cytokine and cytokine receptor pathway. The hub genes we find from RCC samples are not only biomarkers, but also may provide the groundwork for a combination therapy approach for RCCs.
Indexed as
Identifiers
26221260PMC4509205What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.